-

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10 at 1:30 p.m. Eastern Time.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com

Industry:

Personalis, Inc.

NASDAQ:PSNL
Release Versions
English

Contacts

Investors:
Caroline Corner
investors@personalis.com
415-202-5678

Media:
pr@personalis.com

More News From Personalis, Inc.

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT Personal molecular residual disease (MRD) test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood that represent residual or recurrent cancer. Clinicians using the NeXT Personal MRD test will now be able to opt-in for additional reporting...

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). The paper, titled "Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy," details results from Dr. Rodrigo Toledo and a leading team at the Vall d’Hebron Institute of Oncology (VHIO)...

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, in the journal Cell. The study, titled "Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction," demonstrates the clinical importance of ultrasensitive, tumor-informed molecular residual disease (MRD) testi...
Back to Newsroom